Lexeo Therapeutics is expected to report zero revenue and a consensus loss of $0.33 per share, while the current stock price of $3.14 trades well below the average analyst target of $20.30.
Investors are primarily focused on clinical execution and data readouts for the company’s lead cardiovascular gene therapy candidates, LX2006 and LX2020.
Recent Phase 1/2 updates for LX2006 demonstrated sustained cardiac improvements in Friedreich’s ataxia patients, and markets are now awaiting a high-dose participant update for LX2020 in late 2026. The company’s cash position of approximately $234 million provides a critical runway into 2028 as it advances the SUNRISE-FA 2 pivotal trial.